Jacobs Levy Equity Management Inc. Takes $607,000 Position in Cardiff Oncology, Inc. (NASDAQ:CRDF)

Jacobs Levy Equity Management Inc. purchased a new stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 139,854 shares of the company's stock, valued at approximately $607,000. Jacobs Levy Equity Management Inc. owned 0.27% of Cardiff Oncology at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Bank of New York Mellon Corp raised its holdings in shares of Cardiff Oncology by 68.7% during the fourth quarter. Bank of New York Mellon Corp now owns 288,615 shares of the company's stock valued at $1,253,000 after acquiring an additional 117,514 shares during the period. HB Wealth Management LLC acquired a new stake in shares of Cardiff Oncology during the fourth quarter valued at approximately $105,000. American Century Companies Inc. grew its position in Cardiff Oncology by 12.8% during the fourth quarter. American Century Companies Inc. now owns 53,955 shares of the company's stock valued at $234,000 after purchasing an additional 6,140 shares in the last quarter. Rhumbline Advisers grew its position in Cardiff Oncology by 24.0% during the fourth quarter. Rhumbline Advisers now owns 53,172 shares of the company's stock valued at $231,000 after purchasing an additional 10,290 shares in the last quarter. Finally, Barclays PLC grew its position in Cardiff Oncology by 291.9% during the third quarter. Barclays PLC now owns 53,089 shares of the company's stock valued at $141,000 after purchasing an additional 39,542 shares in the last quarter. Institutional investors and hedge funds own 16.29% of the company's stock.

Cardiff Oncology Stock Performance

Shares of CRDF opened at $2.81 on Friday. The company's 50 day moving average price is $3.03 and its 200 day moving average price is $3.46. Cardiff Oncology, Inc. has a 52 week low of $2.01 and a 52 week high of $5.64. The company has a market capitalization of $186.94 million, a PE ratio of -2.99 and a beta of 1.81.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.01). Cardiff Oncology had a negative net margin of 6,238.17% and a negative return on equity of 73.97%. The company had revenue of $0.11 million for the quarter, compared to analysts' expectations of $0.09 million. On average, equities analysts forecast that Cardiff Oncology, Inc. will post -0.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright boosted their price objective on shares of Cardiff Oncology from $17.00 to $18.00 and gave the company a "buy" rating in a research report on Friday, May 9th.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.